Oxidative stress and its biomarkers in systemic lupus erythematosus

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Shah, Dilip ^a   Mahajan, Nidhi ^b   Sah, Sangita ^c   Nath, Swapan K ^d   Paudyal, Bishnuhari ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PANJAB UNIVERSITY   (India)

^c JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Antioxidant therapy; Biomarkers; Oxidative stress; Systemic lupus erythematosus

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ANTIOXIDANT; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CATALASE; DNA; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; ISOPROSTANE DERIVATIVE; LIPID; MALONALDEHYDE; NITROGEN DERIVATIVE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

DNA DAMAGE; DRUG EFFICACY; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN INTERACTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; CLINICAL TRIAL (TOPIC); GENETICS; LIPID PEROXIDATION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PROGNOSIS;

ANTIOXIDANTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; LIPID PEROXIDATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROGNOSIS; REACTIVE OXYGEN SPECIES;

EID: 84899129832     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-21-23     Document Type: Review

References (107)

1. Sources of autoantigens in systemic lupus erythematosus. Graham KL, Utz PJ, Curr Opin Rheumatol 2005 17 513 517 10.1097/01.bor.0000171215.87993.6b 16093826
2. Soluble granzyme B and cytotoxic T lymphocyte activity in the pathogenesis of systemic lupus erythematosus. Shah D, Kiran R, Wanchu A, Bhatnagar A, Cell Immunol 2011 269 16 21 10.1016/j.cellimm.2011.03.004 21458778
3. Apoptosis in the pathogenesis of systemic lupus erythematosus. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J, Lupus 2008 17 371 375 10.1177/0961203308089990 18490410
4. Autoimmunity and oxidatively modified autoantigens. Kurien BT, Scofield RH, Autoimmun Rev 2008 7 567 573 10.1016/j.autrev.2008.04.019 18625446
5. Oxygen free radicals and systemic autoimmunity. Ahsan H, Ali A, Ali R, Clin Exp Immunol 2003 131 398 404 10.1046/j.1365-2249.2003.02104.x 12605691
6. Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Kim-Howard X, Sun C, Molineros JE, Maiti AK, Chandru H, Adler A, Wiley GB, Kaufman KM, Kottyan L, Guthridge JM, Rasmussen A, Kelly J, Sánchez E, Raj P, Li QZ, Bang SY, Lee HS, Kim TH, Kang YM, Suh CH, Chung WT, Park YB, Choe JY, Shim SC, Lee SS, Han BG, Olsen NJ, Karp DR, Moser K, Pons-Estel BA, et al. Hum Mol Genet 2014 23 1656 1668 10.1093/hmg/ddt532 24163247
7. The NRF2 gene variant, -653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus. Cordova EJ, Velazquez-Cruz R, Centeno F, Baca V, Orozco L, Lupus 2010 19 1237 1242 10.1177/0961203310367917 20507872
8. Catalase -262C > T polymorphism in systemic lupus erythematosus in Poland. Warchol T, Lianeri M, Wudarski M, Lacki JK, Jagodzinski PP, Rheumatol Int 2008 28 1035 1039 10.1007/s00296-008-0569-9 18368408
9. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of cigarette smoking and systemic lupus erythematosus in a Japanese population. Kiyohara C, Washio M, Horiuchi T, Asami T, Ide S, Atsumi T, Kobashi G, Takahashi H, Tada Y, Scand J Rheumatol 2012 41 103 109 10.3109/03009742.2011.608194 22217397
10. Association of homozygosity for glutathione-S-transferase GSTM1 null alleles with the Ro+/La- autoantibody profile in patients with systemic lupus erythematosus. Ollier W, Davies E, Snowden N, Alldersea J, Fryer A, Jones P, Strange R, Arthritis Rheum 1996 39 1763 1764 10.1002/art.1780391023 8843871
11. Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus. Mansour RB, Lassoued S, Gargouri B, El Gaid A, Attia H, Fakhfakh F, Scand J Rheumatol 2008 37 103 108 10.1080/ 03009740701772465 18415766
12. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Ben Mansour R, Lassoued S, Elgaied A, Haddouk S, Marzouk S, Bahloul Z, Masmoudi H, Attia H, Aifa MS, Fakhfakh F, Scand J Rheumatol 2010 39 247 253 10.3109/03009740903362511 20429675
13. Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus. Jovanovic V, Abdul Aziz N, Lim YT, Ng Ai Poh A, Jin Hui Chan S, Ho Xin Pei E, Lew FC, Shui G, Jenner AM, Bowen L, McKinney EF, Lyons PA, Kemeny MD, Smith KG, Wenk MR, Macary PA, PLoS One 2013 8 55639 10.1371/journal.pone.0055639 23409013
14. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Shah D, Kiran R, Wanchu A, Bhatnagar A, Immunol Lett 2010 129 7 12 10.1016/j.imlet.2010.01.005 20105444
15. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, Horkko S, Witztum JL, Arthritis Rheum 2005 52 192 200 10.1002/art.20780 15641060
16. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. Tewthanom K, Janwityanuchit S, Totemchockchyakarn K, Panomvana D, J Pharm Pharm Sci 2008 11 30 34 18801305
17. Correlation of serum measures of nitric oxide production with lupus disease activity. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M, J Rheumatol 1999 26 318 324 9972965
18. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Lopez LR, Simpson DF, Hurley BL, Matsuura E, Ann N Y Acad Sci 2005 1051 313 322 10.1196/annals.1361.073 16126973
19. Altered redox state and apoptosis in the pathogenesis of systemic lupus erythematosus. Shah D, Sah S, Wanchu A, Wu MX, Bhatnagar A, Immunobiology 2013 218 620 627 10.1016/j.imbio.2012.07.030 22940256
20. Relationship between T lymphocyte subsets and cortisol in systemic lupus erythematosus. Shah D, Kiran R, Wanchu A, Bhatnagar A, Kathmandu Univ Med J (KUMJ) 2009 7 213 219 20071865
21. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Shah D, Aggarwal A, Bhatnagar A, Kiran R, Wanchu A, Free Radic Res 2011 45 559 567 10.3109/10715762.2011.555765 21284579
22. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Shah D, Wanchu A, Bhatnagar A, Immunobiology 2011 216 1010 1017 10.1016/j.imbio.2011.04.001 21601309
23. Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus. Perl A, Gergely P Jr, Banki K, Int Rev Immunol 2004 23 293 313 10.1080/08830180490452576 15204090
24. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Perl A, Nat Rev Rheumatol 2013 9 674 686 10.1038/nrrheum.2013.147 24100461
25. Oxidative stress and antioxidant defense mechanism in glomerular diseases. Turi S, Nemeth I, Torkos A, Saghy L, Varga I, Matkovics B, Nagy J, Free Radic Biol Med 1997 22 161 168 10.1016/S0891-5849(96)00284-5 8958140
26. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Hassan SZ, Gheita TA, Kenawy SA, Fahim AT, El-Sorougy IM, Abdou MS, Int J Rheum Dis 2011 14 325 331 10.1111/j.1756-185X.2011.01630.x 22004228
27. Lipid peroxidation in systemic lupus erythematosus. Kurien BT, Scofield RH, Indian J Exp Biol 2006 44 349 356 16708886
28. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Taysi S, Gul M, Sari RA, Akcay F, Bakan N, Clin Chem Lab Med 2002 40 684 688 12241014
29. Lipid peroxidase and erythrocyte redox system in systemic vasculitides treated with corticoids. Effect of vitamin E administration. Serban MG, Balanescu E, Nita V, Rom J Intern Med 1994 32 283 289 7613501
30. Oxidative stress and antioxidant parameters in a Turkish group of patients with active and inactive systemic lupus erythematosus. Turgay M, Durak I, Erten S, Ertugrul E, Devrim E, Avci A, Turgay F, APLAR J Rheumatol 2007 10 101 106 10.1111/j.1479-8077.2007.00268.x
31. Oxidative stress and fatigue in systemic lupus erythematosus. Segal BM, Thomas W, Zhu X, Diebes A, McElvain G, Baechler E, Gross M, Lupus 2012 21 984 992 10.1177/0961203312444772 22508802
32. Impaired antioxidant status and decreased dietary intake of antioxidants in patients with systemic lupus erythematosus. Bae SC, Kim SJ, Sung MK, Rheumatol Int 2002 22 238 243 10.1007/s00296-002-0241-8 12426662
33. 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. Abou-Raya A, El-Hallous D, Fayed H, Clin Invest Med 2004 27 306 311 15675110
34. Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus. Mohan IK, Das UN, Prostaglandins Leukot Essent Fatty Acids 1997 56 193 198 10.1016/S0952-3278(97)90533-0 9089797
35. The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Ayudhya DPN, J Clin Pharm Ther 2009 9999
36. Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. Morgan PE, Sturgess AD, Davies MJ, Free Radic Res 2009 43 117 127 10.1080/10715760802623896 19096973
37. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. Morgan PE, Sturgess AD, Hennessy A, Davies MJ, Free Radic Res 2007 41 1301 1312 10.1080/ 10715760701684809 17957542
38. [Study on the relationship between protein oxidation and disease activity in systemic lupus erythematosus]. Zhang Q, Ye DQ, Chen GP, Zhonghua Liu Xing Bing Xue Za Zhi 2008 29 181 184 18686862
39. Oxidative protein damage and antioxidant status in systemic lupus erythematosus. Zhang Q, Ye DQ, Chen GP, Zheng Y, Clin Exp Dermatol 2010 35 287 294 10.1111/j.1365-2230.2009.03437.x 19874339
40. 3-Nitrotyrosine: a biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions. Ahsan H, Hum Immunol 2013 74 1392 1399 10.1016/j.humimm.2013.06.009 23777924
41. 8-Hydroxydeoxyguanosine. A marker of oxidative DNA damage in systemic lupus erythematosus. Lunec J, Herbert K, Blount S, Griffiths HR, Emery P, FEBS Lett 1994 348 131 138 10.1016/0014-5793(94)00583-4 8034028
42. Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Evans MD, Cooke MS, Akil M, Samanta A, Lunec J, Biochem Biophys Res Commun 2000 273 894 898 10.1006/bbrc.2000.3078 10891343
43. Effect of environmental changes on oxidative deoxyribonucleic acid (DNA) damage in systemic lupus erythematosus. Maeshima E, Liang XM, Otani H, Mune M, Yukawa S, Arch Environ Health 2002 57 425 428 10.1080/00039890209601432 12641184
44. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Ho CY, Wong CK, Li EK, Tam LS, Lam CW, Rheumatology (Oxford) 2003 42 117 122 10.1093/rheumatology/keg045 12509624
45. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A, Rheumatol Int 1998 18 41 43 10.1007/s002960050055 9782531
46. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Turrens JF, Boveris A, Biochem J 1980 191 421 427 6263247
47. Hydroperoxide metabolism in mammalian organs. Chance B, Sies H, Boveris A, Physiol Rev 1979 59 527 605 37532
48. Immunogenicity of mitochondrial DNA modified by hydroxyl radical. Alam K, Moinuddin, Jabeen S, Cell Immunol 2007 247 12 17 10.1016/j.cellimm.2007.06.007 17716639
49. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Vignais PV, Cell Mol Life Sci 2002 59 1428 1459 10.1007/s00018-002-8520-9 12440767
50. Deranged bioenergetics and defective redox capacity in T lymphocytes and neutrophils are related to cellular dysfunction and increased oxidative stress in patients with active systemic lupus erythematosus. Li KJ, Wu CH, Hsieh SC, Lu MC, Tsai CY, Yu CL, Clin Dev Immunol 2012 2012 548516 22007252
51. Cavin1; a regulator of lung function and macrophage phenotype. Govender P, Romero F, Shah D, Paez J, Ding SY, Liu L, Gower A, Baez E, Aly SS, Pilch P, Summer R, PLoS One 2013 8 62045 10.1371/journal.pone.0062045 23634221
52. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Ahmad R, Rasheed Z, Ahsan H, Immunopharmacol Immunotoxicol 2009 31 388 396 10.1080/08923970802709197 19555204
53. Peroxynitrite: a biologically significant oxidant. Murphy MP, Packer MA, Scarlett JL, Martin SW, Gen Pharmacol 1998 31 179 186 10.1016/S0306-3623(97) 00418-7 9688457
54. Oxidative stress in environmental-induced carcinogenesis. Mena S, Ortega A, Estrela JM, Mutat Res 2009 674 36 44 10.1016/j.mrgentox.2008.09.017 18977455
55. Radiation-induced peroxidation and fragmentation of lipids in a model membrane. Shadyro OI, Yurkova IL, Kisel MA, Int J Radiat Biol 2002 78 211 217 10.1080/09553000110104065 11869476
56. Hydroxyl radical modification of immunoglobulin g generated cross-reactive antibodies: its potential role in systemic lupus erythematosus. Al-Shobaili HA, Al Robaee AA, Alzolibani A, Khan MI, Rasheed Z, Clin Med Insights Arthritis Musculoskelet Disord 2011 4 11 19 21487454
57. Hydroxyl radical modification of polyguanylic acid: role of modified guanine in circulating SLE anti-DNA autoantibodies. Garg DK, Moinuddin, Ali R, Immunol Invest 2003 32 187 199 10.1081/IMM-120022978 12916708
58. Methods to assess free radicals and oxidative stress in biological systems. Rimbach G, Hohler D, Fischer A, Roy S, Virgili F, Pallauf J, Packer L, Arch Tierernahr 1999 52 203 222 10.1080/17450399909386163 10553486
59. Prooxidant-initiated lipid peroxidation in isolated rat hepatocytes: detection of 4-hydroxynonenal- and malondialdehyde-protein adducts. Hartley DP, Kroll DJ, Petersen DR, Chem Res Toxicol 1997 10 895 905 10.1021/tx960181b 9282839
60. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. Calingasan NY, Uchida K, Gibson GE, J Neurochem 1999 72 751 756 10.1046/j.1471-4159.1999.0720751.x 9930749
61. Determination of carbonyl content in oxidatively modified proteins. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER, Methods Enzymol 1990 186 464 478 1978225
62. Interaction between glutathione and apoptosis in systemic lupus erythematosus. Shah D, Sah S, Nath SK, Autoimmun Rev 2013 12 741 751 10.1016/j.autrev.2012.12.007 23279845
63. Antibodies against 4-hydroxy-2-nonenal modified epitopes recognized chromatin and its oxidized forms: role of chromatin, oxidized forms of chromatin and 4-hydroxy-2-nonenal modified epitopes in the etiopathogenesis of SLE. Al-Shobaili HA, Al Robaee AA, Alzolibani AA, Rasheed Z, Dis Markers 2012 33 19 34 10.1155/2012/532497 22710866
64. Biomarkers. Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Paulsen H, Verhagen H, Astley SB, Mol Aspects Med 2002 23 101 208 10.1016/S0098-2997(02)00017-1 12079771
65. Protein-bound 4-hydroxy-2-nonenal: an endogenous triggering antigen of antI-DNA response. Toyoda K, Nagae R, Akagawa M, Ishino K, Shibata T, Ito S, Shibata N, Yamamoto T, Kobayashi M, Takasaki Y, Matsuda T, Uchida K, J Biol Chem 2007 282 25769 25778 10.1074/jbc.M703039200 17588942
66. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Halliwell B, Am J Med 1991 91 14S 22S
67. Role of reactive oxygen species in biological processes. Sies H, Klin Wochenschr 1991 69 965 968 10.1007/BF01645140 1798292
68. Relationship between iron metabolism, oxidative stress, and insulin resistance in patients with systemic lupus erythematosus. Lozovoy MA, Simao AN, Oliveira SR, Iryioda TM, Panis C, Cecchini R, Dichi I, Scand J Rheumatol 2013 42 303 310 10.3109/03009742.2012.754942 23424997
69. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Schafer FQ, Buettner GR, Free Radic Biol Med 2001 30 1191 1212 10.1016/S0891-5849(01)00480-4 11368918
70. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C, Proc Natl Acad Sci U S A 1998 95 3071 3076 10.1073/pnas.95.6.3071 9501217
71. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. Messina JP, Lawrence DA, J Immunol 1989 143 1974 1981 2789253
72. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Suwannaroj S, Lagoo A, Keisler D, McMurray RW, Lupus 2001 10 258 265 11341102
73. Superoxide dismutases and their impact upon human health. Johnson F, Giulivi C, Mol Aspects Med 2005 26 340 352 10.1016/j.mam.2005.07.006 16099495
74. Metabolism of hydrogen peroxide in isolated hepatocytes: relative contributions of catalase and glutathione peroxidase in decomposition of endogenously generated H2O2. Jones DP, Eklow L, Thor H, Orrenius S, Arch Biochem Biophys 1981 210 505 516 10.1016/0003-9861(81)90215-0 7305340
75. Catalase in vitro. Aebi H, Methods Enzymol 1984 105 121 126 6727660
76. Selenium-dependent glutathione peroxidase and other selenoproteins: their synthesis and biochemical roles. Gamble SC, Wiseman A, Goldfarb PS, J Chem Technol Biotech 1999 68 123 134
77. Cellular thiols and redox-regulated signal transduction. Sen CK, Curr Top Cell Regul 2000 36 1 30 10842745
78. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Halliwell B, Whiteman M, Br J Pharmacol 2004 142 231 255 10.1038/sj.bjp.0705776 15155533
79. Biomarkers of oxidative damage in human disease. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A, Clin Chem 2006 52 601 623 10.1373/clinchem.2005.061408 16484333
80. Identification of ROS using oxidized DCFDA and flow-cytometry. Eruslanov E, Kusmartsev S, Methods Mol Biol 2010 594 57 72 10.1007/978-1-60761-411-1-4 20072909
81. Lipid peroxidation affects red blood cells membrane properties in patients with systemic lupus erythematosus. Spengler MI, Svetaz MJ, Leroux MB, Bertoluzzo SM, Parente FM, Bosch P, Clin Hemorheol Microcirc 2013
82. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Uchida K, Prog Lipid Res 2003 42 318 343 10.1016/S0163-7827(03)00014-6 12689622
83. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Cracowski JL, Durand T, Bessard G, Trends Pharmacol Sci 2002 23 360 366 10.1016/S0165-6147(02)02053-9 12377577
84. Validation of a novel ELISA for measurement of MDA-LDL in human plasma. Bevan RJ, Durand MF, Hickenbotham PT, Kitas GD, Patel PR, Podmore ID, Griffiths HR, Waller HL, Lunec J, Free Radic Biol Med 2003 35 517 527 10.1016/S0891- 5849(03)00359-9 12927601
85. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU, Antioxid Redox Signal 1999 1 255 284 10.1089/ars.1999.1.3-255 11229439
86. Differential oxidative modification of proteins in MRL+/+ and MRL/lpr mice: increased formation of lipid peroxidation-derived aldehyde-protein adducts may contribute to accelerated onset of autoimmune response. Wang G, Li H, Firoze Khan M, Free Radic Res 2012 46 1472 1481 10.3109/10715762.2012.727209 22950782
87. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF, Arthritis Rheum 2010 62 2064 2072 20201076
88. Evidence that the E2-isoprostane, 15-E2t-isoprostane (8-iso-prostaglandin E2) is formed in vivo. Morrow JD, Scruggs J, Chen Y, Zackert WE, Roberts LJ 2nd, J Lipid Res 1998 39 1589 1593 9717718
89. Biological markers of oxidative stress: applications to cardiovascular research and practice. Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA, Redox Biol 2013 1 483 491 10.1016/j.redox.2013.07.006 24251116
90. Isoprostanes: novel bioactive products of lipid peroxidation. Basu S, Free Radic Res 2004 38 105 122 10.1080/10715760310001646895 15104204
91. Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, Shintani A, Yu C, Stein CM, Lupus 2007 16 195 200 17432105
92. Quantification and significance of protein oxidation in biological samples. Shacter E, Drug Metab Rev 2000 32 307 326 10.1081/DMR-100102336 11139131
93. Protein carbonyl groups as biomarkers of oxidative stress. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R, Clin Chim Acta 2003 329 23 38 10.1016/S0009-8981(03)00003-2 12589963
94. [Oxidative DNA damage-analysis and clinical significance]. Zaremba T, Olinski R, Postepy Biochem 2010 56 124 138 20873107
95. Determination of urinary 8-hydroxydeoxyguanosine by automated coupled-column high performance liquid chromatography: a powerful technique for assaying in vivo oxidative DNA damage in cancer patients. Tagesson C, Kallberg M, Klintenberg C, Starkhammar H, Eur J Cancer 1995 31A 934 940 7646926
96. A new automated method to analyze urinary 8-hydroxydeoxyguanosine by a high-performance liquid chromatography-electrochemical detector system. Kasai H, J Radiat Res 2003 44 185 189 10.1269/jrr.44.185 13678349
97. Quantitative determination of urinary 8-hydroxydeoxyguanosine (8-OH-dg) by using ELISA. Saito S, Yamauchi H, Hasui Y, Kurashige J, Ochi H, Yoshida K, Res Commun Mol Pathol Pharmacol 2000 107 39 44 11334369
98. Comparison between high-performance liquid chromatography and enzyme-linked immunosorbent assay for the determination of 8-hydroxy-2′- deoxyguanosine in human urine. Shimoi K, Kasai H, Yokota N, Toyokuni S, Kinae N, Cancer Epidemiol Biomarkers Prev 2002 11 767 770 12163331
99. Comparison of analyses of urinary 8-hydroxy-2′-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Hu CW, Wu MT, Chao MR, Pan CH, Wang CJ, Swenberg JA, Wu KY, Rapid Commun Mass Spectrom 2004 18 505 510 10.1002/rcm.1367 14966860
100. Oxidative stress in human aging and mitochondrial disease-consequences of defective mitochondrial respiration and impaired antioxidant enzyme system. Wei YH, Lu CY, Wei CY, Ma YS, Lee HC, Chin J Physiol 2001 44 1 11 11403514
101. The importance of glutathione in human disease. Townsend DM, Tew KD, Tapiero H, Biomed Pharmacother 2003 57 145 155 10.1016/S0753-3322(03)00043-X 12818476
102. [Pro- and antioxidant blood system in patients with rheumatoid arthritis and systemic lupus erythematosus]. Vipartene D, Iasiulevichute L, Butkene B, Valiukene K, Keturkene A, Redaitene E, Ter Arkh 2006 78 10 14
103. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A, Arthritis Rheum 2013 65 1313 1318 10.1002/art.37893 23400548
104. Circulating endothelial cells as a marker of vascular dysfunction in patients with systemic lupus erythematosus by real-time polymerase chain reaction. Attia FM, Maaty A, Kalil FA, Arch Pathol Lab Med 2011 135 1482 1485 10.5858/arpa.2010-0731-OA 22032577
105. Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. Kudaravalli J, Indian J Pharmacol 2011 43 311 315 10.4103/0253-7613.81511 21713097
106. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, Miklossy G, Jimah J, Doherty E, Tily H, Francis L, Garcia R, Dawood M, Yu J, Ramos I, Coman I, Faraone SV, Phillips PE, Perl A, Arthritis Rheum 2012 64 2937 2946 10.1002/art.34502 22549432
107. Cystamine attenuates lupus-associated apoptosis of ventricular tissue by suppressing both intrinsic and extrinsic pathways. Tzang BS, Hsu TC, Kuo CY, Chen TY, Chiang SY, Li SL, Kao SH, J Cell Mol Med 2012 16 2104 2111 10.1111/j.1582-4934.2011.01511.x 22212591